硫化氢在体外和体内保护视网膜神经节细胞免受青光眼性损伤
本研究在Sprague-Dawley大鼠通过巩膜外静脉烧灼升高眼压建立实验性青光眼模型,7周后取视网膜行无标记质谱分析;体外将视网膜外植体暴露于升高的静水压或氧化应激(H2O2),加或不加缓释硫化氢供体GYY4137;体内在急性缺血性损伤或视神经夹伤动物玻璃体腔注射GYY4137。结果显示眼压升高导致显著视网膜神经节细胞丢失(P < 0.001),硫化氢生成酶3-巯基硫转移酶在眼压升高后视网膜内上调3倍,GYY4137在体外呈浓度依赖性保护视网膜神经节细胞(P < 0.005),在体内保留急性缺血性损伤和视神经夹伤后的视网膜神经节细胞(P < 0.0001),玻璃体腔注射GYY4137后视网膜血管直径增大(P < 0.0001)。作者认为硫化氢可能通过清除活性氧和扩张视网膜血管保护视网膜神经节细胞,可能成为青光眼的新型神经保护剂。
要点
- 眼压升高导致视网膜神经节细胞显著丢失(P < 0.001),硫化氢生成酶3-巯基硫转移酶在眼压升高后视网膜内上调3倍。
- GYY4137在体外呈浓度依赖性保护视网膜神经节细胞对抗升高的压力和氧化应激(P < 0.005)。
- 玻璃体腔注射GYY4137在体内保留急性缺血性损伤和视神经夹伤后的视网膜神经节细胞(P < 0.0001)。
核心结论
- 硫化氢在实验性青光眼中被特异性调节,可能通过清除活性氧和扩张视网膜血管保护视网膜神经节细胞,可能成为青光眼的新型神经保护剂。
研究设计与样本
- 在Sprague-Dawley大鼠通过巩膜外静脉烧灼升高眼压,7周后处死动物取视网膜行无标记质谱分析。
- 体外将视网膜外植体暴露于升高的静水压或氧化应激(H2O2),加或不加缓释硫化氢供体GYY4137。
- 体内在急性缺血性损伤或视神经夹伤动物玻璃体腔注射GYY4137,计数视网膜铺片中的Brn3a+视网膜神经节细胞并用光学相干断层扫描(OCT)检查血管。
- 比较采用t检验和方差分析(P < 0.05)。
主要发现
- 眼压升高导致显著视网膜神经节细胞丢失(P < 0.001)。
- 硫化氢生成酶3-巯基硫转移酶在眼压升高后视网膜内上调3倍。
- GYY4137在体外呈浓度依赖性保护视网膜神经节细胞对抗升高的压力和氧化应激(P < 0.005)。
- 体内玻璃体腔注射GYY4137保留急性缺血性损伤和视神经夹伤后的视网膜神经节细胞(P < 0.0001)。
- 玻璃体腔注射GYY4137后视网膜血管直径增大(P < 0.0001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Hydrogen sulfide (H2S) is recognized as a novel third signaling molecule and gaseous neurotransmitter. Recently, cell protective properties within the central nervous and cardiovascular system have been proposed. Our purpose was to analyze the expression and neuroprotective effects of H2S in experimental models of glaucoma. METHODS: Elevated IOP was induced in Sprague-Dawley rats by means of episcleral vein cauterization. After 7 weeks, animals were killed and the retina was analyzed with label-free mass spectrometry. In vitro, retinal explants were exposed to elevated hydrostatic pressure or oxidative stress (H2O2), with and without addition of a slow-releasing H2S donor Morpholin-4-ium-methoxyphenyl-morpholino-phosphinodithioate (GYY4137). In vivo, GYY4137 was injected intravitreally in animals with acute ischemic injury or optic nerve crush. Brn3a+ retinal ganglion cells (RGCs) were counted in retinal flat mounts and compared. Optical coherence tomography (OCT) was performed to examine the vessels. Comparisons were made by t-test and ANOVA (P < 0.05). RESULTS: IOP elevation caused significant RGC loss (P < 0.001); 3-mercaptosulfurtransferase, an H2S producing enzyme, showed a 3-fold upregulation within the retina after IOP elevation. GYY4137 protected RGCs against elevated pressure and oxidative stress in vitro depending on the concentration used (P < 0.005). In vivo, intravitreal administration of GYY4137 preserved RGCs from acute ischemic injury and optic nerve crush (P < 0.0001). Retinal vessel diameters enlarged after intravitreal GYY4137 injection (P < 0.0001). CONCLUSIONS: H2S is specifically regulated in experimental glaucoma. By scavenging reactive oxygen species and dilating retinal vessels, H2S may protect RGCs from pressure and oxidative stress-induced RGC loss in vitro and in vivo. Therefore, H2S might be a novel neuroprotectant in glaucoma.
引用
- Liu H, Anders F, Thanos S, et al. Hydrogen Sulfide Protects Retinal Ganglion Cells Against Glaucomatous Injury In Vitro and In Vivo. Invest Ophthalmol Vis Sci. 2017. PMID: 28986598. doi:10.1167/iovs.17-22200
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。